Cardiovascular disease prevention and treatment

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 81, Issue 2-3, 2009, Pages 193-198

  von Schacky, Clemens ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Omegametrix GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOCOSAHEXAENOIC ACID; DOCOSAHEXAENOIC ACID PLUS ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PLACEBO; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID;

ACUTE CORONARY SYNDROME; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DIETARY REFERENCE INTAKE; FAT INTAKE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART REINFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID RAFT; NUTRITIONAL COUNSELING; PRIORITY JOURNAL; SUDDEN DEATH;

ARRHYTHMIAS, CARDIAC; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DEATH, SUDDEN, CARDIAC; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; ERYTHROCYTES; EUROPE; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; INCIDENCE; JAPAN; MYOCARDIAL INFARCTION; PREGNANCY; RISK; UNITED STATES;

EID: 69549097632     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2009.05.009     Document Type: Article

References (54)

1. Zipes D.P., Camm A.J., Borggrefe M., et al., American College of Cardiology/American Heart Association Task Force, European Society of Cardiology Committee for Practice Guidelines, European Heart Rhythm Association, Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American college of cardiology/American heart association task force and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the European heart rhythm association and the heart rhythm society. Circulation 114 (2006) e385-e484
2. von Schacky C., and Harris W.S. Cardiovascular benefits of omega-3 fatty acids. Cardiovasc. Res. 73 (2007) 310-315
3. von Schacky C. Omega-3 fatty acids pro-arrhythmic, anti-arrhythmic or both?. Curr. Opin. Nutr. Metab. Care 11 (2008) 94-99
4. Huikuri H.V., Mäkikallio T.H., Raatikainen M.J., Perkiömäki J., Castellanos A., and Myerburg R.J. Prediction of sudden cardiac death: appraisal of the studies and methods assessing the risk of sudden arrhythmic death. Circulation 108 (2003) 110-115
5. Moss A.J., Zareba W., Hall W.J., et al. Multicenter automatic defibrillator implantation trial II investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 346 (2002) 877-883
6. Harris W.S., and von Schacky C. The omega-3 index: a new risk factor for death from coronary heart disease?. Prev. Med. 39 (2004) 212-220
7. Harris W.S., Sands S.A., Windsor S.L., et al. Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation 110 (2004) 1645-1649
8. Metcalf R.G., James M.J., Gibson R.A., et al. Effects of fish-oil supplementation on myocardial fatty acids in humans. Am. J. Clin. Nutr. 85 (2007) 1222-1228
9. Sun Q., Ma J., Campos H., Hankinson S.E., and Hu F.B. Comparison between plasma and erythrocyte fatty acid content as biomarkers of fatty acid intake in US women. Am. J. Clin. Nutr. 86 (2007) 74-81
10. Sands S.A., Reid K.J., Windsor S.L., and Harris W.S. The impact of age, body mass index, and fish intake on the EPA and DHA content of human erythrocytes. Lipids 40 (2005) 343-347
11. Iso H., Kobayashi M., Ishihara J., et al., JPHC Study Group. Intake of fish and n-3 fatty acids and risk of coronary heart disease among Japanese: the Japan public health center-based (JPHC) study cohort I. Circulation 113 (2006) 195-202
12. Itomura M., Fujioka S., Hamazaki K., et al. Factors influencing EPA+DHA levels in red blood cells in Japan. In Vivo 22 (2008) 131-135
13. von Schacky C., Angerer P., Kothny W., Theisen K., and Mudra H. The effect of dietary ω-3 fatty acids on coronary atherosclerosis. A randomized, double-blind placebo-controlled trial. Ann. Int. Med. 30 (1999) 554-562
14. Siscovick D.S., Raghunathan T.E., King I., et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. J. Am. Med. Assoc. 275 (1995) 836-837
15. London B., Albert C., Anderson M.E., et al. Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the national heart, lung, and blood institute and office of dietary supplements omega-3 fatty acids and their role in cardiac arrhythmogenesis workshop. Circulation 116 (2007) e320-e335
16. Den Ruijter H.M., Berecki G., Opthof T., Verkerk A.O., Zock P.L., and Coronel R. Pro- and antiarrhythmic properties of a diet rich in fish oil. Cardiovasc. Res. 73 (2007) 316-325
17. Wilhelm M., Tobias R., Asskali F., et al. Red blood cell omega-3 fatty acids and the risk of ventricular arrhythmias in patients with heart failure. Am. Heart J. 155 (2008) 971-977
18. Mozaffarian D., Prineas R.J., Stein P.K., and Siscovick D.S. Dietary fish and n-3 fatty acid intake and cardiac electrophysiologic parameters in humans. J. Am. Coll. Cardiol. 48 (2006) 478-484
19. O'Keefe Jr. J.H., Abuissa H., Sastre A., Steinhaus D.M., and Harris W.S. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am. J. Cardiol. 97 (2006) 1127-1130
20. Harris W.S., Gonzales M., Laney N., Sastre A., and Borkon A.M. Effects of omega-3 fatty acids on heart rate in cardiac transplant recipients. Am. J. Cardiol. 98 (2006) 1393-1395
21. Leaf A., Albert C.M., Josephson M., et al., for the Fatty Acid Antiarrhythmia Trial Investigators. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 112 (2005) 2762-2768
22. Raitt M.H., Connor W.E., Morris C., et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators. A randomized controlled trial. J. Am. Med. Assoc. 293 (2005) 2884-2891
23. Brouwer I.A., Zock P.L., Camm A.J., et al., SOFA Study Group. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. J. Am. Med. Assoc. 295 (2006) 2613-2619
24. Jenkins D.J., Josse A.R., Beyene J., et al. Fish-oil supplementation in patients with implantable cardioverter defibrillators: a meta-analysis. CMAJ 178 (2008) 157-164
25. Albert C.M. Omega-3 fatty acids and ventricular arrhythmias: nothing is simple. Am. Heart J. 155 (2008) 967-970
26. Burr M.L., Fehily A.M., Gilbert J.F., et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial infarction: diet and reinfarction trial (DART). Lancet 2 (1989) 757-761
27. Marchioli R., Barzi F., Bomba E., et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction. Time-course analysis of the results of the gruppo Italiano per lo studio della sopravvivenza nell′infarcto miocardio (GISSI)-prevenzione. Circulation 105 (2002) 1897-1903
28. Ness A.R., Ashfield-Watt P.A.L., Whiting J.M., Smith G.D., Hughes J., and Burr M.L. The long-term effect of dietary advice on the diet of men with angina: the diet and angina randomized trial. J. Hum. Nutr. Diet. 17 (2004) 117-119
29. Yokoyama M., Origasa H., Matsuzaki M., et al., Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369 (2007) 1090-1098 (Erratum in: Lancet 370 (2007) 220)
30. Mozaffarian D., and Rimm E.B. Fish intake, contaminants, and human health: evaluating the risks and the benefits. J. Am. Med. Assoc. 296 (2006) 1885-1899 (Erratum in: J Am Med Assoc 297 (2006) 590)
31. Wang C., Harris W.S., Chung M., et al. n-3 fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am. J. Clin. Nutr. 84 (2006) 5-17
32. von Schacky C. Omega-3 fatty acids and cardiovascular disease. Curr. Opin. Nutr. Metab. Care 10 (2007) 129-136
33. Block R.C., Harris W.S., Reid K.J., Sands S.A., and Spertus J.A. EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis 197 (2008) 821-828
34. von Schacky C. n-3 PUFA in CVD: influence of cytokine polymorphism. Proc. Nutr. Soc. 66 (2007) 166-170
35. De Caterina R., and Zampolli A. Omega-3 fatty acids, atherogenesis and endothelial activation. J. Cardiovasc. Med. (Hagerstown) 8 Suppl. 1 (2007) S11-S14
36. B. Holub, Conventional risk factors, Prostagl. Leukotr. Essent. Fatty Acids, in press.
37. von Schacky C. A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. Vasc. Health Risk Manage. 2 (2006) 251-262
38. Nishizawa H., Hamazaki K., Hamazaki T., Fujioka S., and Sawazaki S. The relationship between tissue RBC n-3 fatty acids and pulse wave velocity. In Vivo 20 (2006) 307-310
39. Tomiyama H., Takazawa K., Osa S., et al. Do eicosapentaenoic acid supplements attenuate age-related increases in arterial stiffness in patients with dyslipidemia?: a preliminary study. Hypertens. Res. 28 (2005) 651-655
40. Hjerkinn E.M., Abdelnoor M., Breivik L., et al. Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. 1: Eur. J. Cardiovasc. Prev. Rehabil. 13 (2006) 325-333
41. Eritsland J., Arnesen H., Grønseth K., Fjeld N.B., and Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am. J. Cardiol. 77 (1996) 31-36
42. Balk E.M., Lichtenstein A.H., Chung M., Kupelnick B., Chew P., and Lau J. Effects of omega-3 fatty acids on coronary restenosis, intima-media thickness, and exercise tolerance: a systematic review. Atherosclerosis 184 (2006) 237-246
43. Thies F., Garry J.M., Yaqoob P., et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 361 (2003) 477-485
44. Calo L., Bianconi L., Colivicchi F., et al. N-3 fatty acids for the prevention of atrial fibrillation after coronary bypass surgery. J. Am. Coll. Cardiol. 45 (2005) 1723-1728
45. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., and The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342 (2000) 145-153
46. Fox K.M., and EURopean trial on reduction of cardiac events with Perindopril in stable coronary artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
47. Macchia A., Levantesi G., Franzosi M.G., Geraci E., Maggioni A.P., Marfisi R., Nicolosi G.L., Schweiger C., Tavazzi L., Tognoni G., Valagussa F., Marchioli R., and GISSI-Prevenzione Investigators. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur. J. Heart Fail 7 5 (2005) 904-909
48. Tavazzi L., Tognoni G., Franzosi M.G., et al., GISSI-HF Investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur. J. Heart Fail 6 (2004) 635-641
49. GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 372 (2008) 1223-1230
50. Fonarow G.C. Statins and n-3 supplementation in heart failure. Lancet 372 (2008) 1195-1196
51. Harris W.S. International recommendations for consumption of long-chain omega-3 fatty acids. J. Cardiovasc. Med. (Hagerstown) 8 Suppl. 1 (2007) S50-S52
52. Tardif J.C., Heinonen T., Orloff D., and Libby P. Vascular biomarkers and surrogates in cardiovascular disease. Circulation 113 (2006) 2936-2942
53. Domingo J.L., Bocio A., Falcó G., and Llobet J.M. Benefits and risks of fish consumption: part I. A quantitative analysis of the intake of omega-3 fatty acids and chemical contaminants. Toxicology 230 (2007) 219-226
54. Arterburn L.M., Oken H.A., Bailey Hall E., Hamersley J., and Kuratko C.N. Hoffman JPAlgal-oil capsules and cooked salmon: nutritionally equivalent sources of docosahexaenoic acid. J. Am. Diet. Assoc. 108 (2008) 1204-1209